Search Results for: initial regimen

General Considerations with Initial ART Regimens

Lead Author: Samuel T. Merrick, MD, with the Medical Care Criteria Committee, updated January 2019 The recommended antiretroviral therapy (ART) regimens should work well for the majority of patients, but some circumstances may make one regimen more favorable than another for a given individual. In general, an integrase strand transfer inhibitor (INSTI)-based regimen will be the best … Continue reading “General Considerations with Initial ART Regimens”

General Principles in Choosing an Initial ART Regimen

Lead Author: Samuel T. Merrick, MD, with the Medical Care Criteria Committee, updated January 2019 Goals of antiretroviral therapy (ART): The issue of when to start ART was settled with the publication of the START (Strategic Timing of Antiretroviral Treatment) and TEMPRANO (Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults) studies early in 2015 … Continue reading “General Principles in Choosing an Initial ART Regimen”

General Principles in Choosing a Regimen for Rapid ART Initiation

Lead author Asa Radix, MD, MPH, with the Medical Care Criteria Committee, August 2019 RECOMMENDATIONS GOOD PRACTICE Choosing a Regimen for Rapid ART Initiation The preferred medications for rapid ART initiation are based on the established regimens for persons who are ART naive and are restricted to those that can be safely initiated in the … Continue reading “General Principles in Choosing a Regimen for Rapid ART Initiation”

Available ART Regimens

Lead Author: Samuel T. Merrick, MD, with the Medical Care Criteria Committee, updated August 2019 Note: The recommendations in this guideline pertain to initial antiretroviral therapy (ART) regimens for adults with HIV who are not pregnant. RECOMMENDATIONS Available Antiretroviral Agents and Regimens Each regimen listed below in Tables 1 and 2, preferred and alternative initial ART regimens, … Continue reading “Available ART Regimens”

ART Regimens for oPEP

Medical Care Criteria Committee, updated May 2018 RECOMMENDATIONS Table 1: Recommended Preferred and Alternative Antiretroviral Regimens for oPEP Preferred oPEP Regimen Note: All are oral medications Notes Tenofovir disoproxil fumarate (TDF) 300 mg daily plus emtricitabine (FTC) 200 mg daily plus raltegravir (RAL) 400 mg twice daily or dolutegravir (DTV) 50 mg daily [see DTG safety statement, … Continue reading “ART Regimens for oPEP”

ART Regimens for nPEP

Medical Care Criteria Committee, updated May 2018 RECOMMENDATIONS Post-Exposure Prophylaxis Regimens for Non-Occupational Exposures to HIV  Table 1: Preferred and Alternative Antiretroviral Regimens for nPEP RECOMMENDED Regimen Note: All are oral medications Notes Tenofovir disoproxil fumarate (TDF) 300 mg* daily plus emtricitabine (FTC) 200 mg daily plus raltegravir (RAL) 400 mg twice daily or dolutegravir (DTV) … Continue reading “ART Regimens for nPEP”

Initial Assessment

Medical Care Criteria Committee, October 2014 RECOMMENDATIONS This section provides guidance for assessing non-occupational exposures that occur from blood and body fluid exposures, including sexual and needle-sharing activities unrelated to sexual assault. (Special considerations for PEP following sexual assault are covered in PEP for Victims of Sexual Assault). Situations that may prompt a request for nPEP include … Continue reading “Initial Assessment”

Treatment of HIV-2

Lead author, Sanjiv S. Shah, MD, MPH, AAHIVS, with the Medical Care Criteria Committee, July 2019 RECOMMENDATIONS See ratings definitions Table 1: ART Regimens for Initial Treatment of Nonpregnant Adults With HIV-2* PREFERRED Regimens Single-Tablet Regimens Comments Abacavir/lamivudine/ dolutegravir (ABC/3TC/DTG; Triumeq) Initiate only in patients confirmed to be negative for HLA-B*5701. Initiate only in patients with creatinine clearance (CrCl) … Continue reading “Treatment of HIV-2”

Updates to this Guideline

January 2019 Boosted TDF-containing Regimens No Longer Recommended This committee the MCCC no longer recommends initial ART regimens that include tenofovir disoproxil fumarate (TDF) boosted with either cobicistat (COBI) or ritonavir (RTV). Studies have shown that TDF-related renal toxicity is more common when using TDF in a regimen containing COBI or RTV; therefore, the MCCC does … Continue reading “Updates to this Guideline”